Borut Božič

Prof. Borut Božič

Faculty of Pharmacy, University of Ljubljana, Askerceva cesta 7, 1000 Ljubljana, Slovenia
orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 May 2012 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
RRReinout Raijmakers
Reinout Raijmakers
JBJoyce Jbc van Beers
Joyce Jbc van Beers
MEMahmoud El-Azzouny
Mahmoud El-Azzouny
NVNatasja Fc Visser
Natasja Fc Visser
Borut BožičBorut Božič
Borut Božič
AHAlbert Heck
Albert Heck
Introduction: Rheumatoid arthritis (RA) is an autoimmune disease characterized by inflammation of the joints and the presence of autoantibodies directed against proteins containing the non-standard arginine-derived amino acid citrulline. The protein fibrinogen, which has an essential role in blood clotting, is one of the most prominent citrullinated autoantigens in RA, particularly because it can be found in the inflamed tissue of affected joints. Here, we set out to analyze the presence of citrullinated endogenous peptides in the synovial fluid of RA and arthritic control patients. Methods: Endogenous peptides were isolated from the synovial fluid of RA patients and controls by filtration and solid phase extraction. The peptides were identified and quantified using high-resolution liquid chromatography-mass spectrometry. Results: Our data reveal that the synovial fluid of RA patients contains soluble endogenous peptides, derived from fibrinogen, containing significant amounts of citrulline residues and, in some cases, also phosphorylated serine. Several citrullinated peptides are found to be more abundantly present in the synovial fluid of RA patients compared to patients suffering from other inflammatory diseases affecting the joints. Conclusions: The increased presence of citrullinated peptides in RA patients points toward a possible specific role of these peptides in the immune response at the basis of the recognition of citrullinated peptides and proteins by RA patient autoantibodies.

11 September 2005 in Clinical and Experimental Immunology
Verified
Journal Article
Closed access
PDF file
JPJ. Martinuč Porobič
J. Martinuč Porobič
TAT. Avčin
T. Avčin
Borut BožičBorut Božič
Borut Božič
MKM. Kuhar
M. Kuhar
SČS. Čučnik
S. Čučnik
BRB. Rozman
B. Rozman

21 September 2016 in Pharmacy
Verified
Journal Article
Open access
PDF file
JAJeffrey Atkinson
Jeffrey Atkinson
Kristien De PaepeKristien De Paepe
Kristien De Paepe
APAntonio Sánchez Pozo
Antonio Sánchez Pozo
DRDimitrios Rekkas
Dimitrios Rekkas
Daisy VolmerDaisy Volmer
Daisy Volmer
CSChris Van Schravendijk
Chris Van Schravendijk
This paper presents the results of the second European Delphi round on the ranking of competences for pharmacy practice and compares these data to those of the first round already published. A comparison of the numbers of respondents, distribution by age group, country of residence, etc., shows that whilst the student population of respondents changed from Round 1 to 2, the populations of the professional groups (community, hospital and industrial pharmacists, pharmacists in other occupations and academics) were more stable. Results are given for the consensus of ranking and the scores of ranking of 50 competences for pharmacy practice. This two-stage, large-scale Delphi process harmonized and validated the Quality Assurance in European Pharmacy Education and Training (PHAR-QA) framework and ensured the adoption by the pharmacy profession of a framework proposed by the academic pharmacy community. The process of evaluation and validation of ranking of competences by the pharmacy profession is now complete, and the PHAR-QA consortium will now put forward a definitive PHAR-QA framework of competences for pharmacy practice.

31 July 2008 in Autoimmunity Reviews
Verified
Journal Article
Closed access
JOJ. Omersel
J. Omersel
IJI. Jurgec
I. Jurgec
SČS. Čučnik
S. Čučnik
TKT. Kveder
T. Kveder
BRB. Rozman
B. Rozman
Borut BožičBorut Božič
Borut Božič

17 May 2011 in Clinical Chemistry and Laboratory Medicine (CCLM)
Verified
Journal Article
Closed access
Polona ŽigonPolona Žigon
Polona Žigon
AAAleš Ambrožič
Aleš Ambrožič
SČSaša Čučnik
Saša Čučnik
TKTanja Kveder
Tanja Kveder
BRBlaž Rozman
Blaž Rozman
Borut BožičBorut Božič
Borut Božič
Background: Two approaches for detecting anti-prothrombin antibodies have been described. The first detects antibodies against prothrombin alone and the second, phos-phatidylserine-dependent antiprothrombin antibodies. The latter more often correlate with clinical manifestations of antiphospholipid syndrome and with lupus anticoagulant activity. Methods: In order to increase the capacity of antibody binding, we modified the previously described phosphatidylser-ine-dependent antiprothrombin ELISA and determined their avidity. We examined 203 patients with systemic autoimmune diseases and 222 blood donors. Results: Our modification resulted in a greater intensity of antibody binding to prothrombin on phosphatidylserine-coated plate surfaces compared to the previously described method. By changing ELISA conditions, we were able to detect with one assay the two, presumably different, populations of antiprothrombin antibodies. Diagnostic specificities of both ELISAs for antiphospholipid syndrome were similar (92.5% vs. 93.1%), while the sensitivity of the modified phosphatidylserine-dependent antiprothrombin ELISA was significantly higher than the anti-prothrombin alone ELISA (59% vs. 25%). Low avidity antiprothrombin antibodies were only detected in the modified phosphatidylserine-dependent antiprothrombin ELISA. Four percent of patients with positive phosphatidylserine-dependent antiprothrombin antibodies, showing clinical manifestations of antiphospholipid syndrome, were negative for all other antiphospholipid antibodies. The risk for antiphospholipid syndrome increased with the number of antiphospholipid antibody positivity. Conclusions: We conclude that antibodies detected with a modified phosphatidylserine-dependent antiprothrombin ELISA could improve the diagnosis of antiphospholipid syndrome by offering additional information on the risk for thrombosis, especially in patients negative for other antiphospholipid antibodies.

17 November 2015 in Pharmacy
Verified
Journal Article
Open access
PDF file
JAJeffrey Atkinson
Jeffrey Atkinson
Kristien De PaepeKristien De Paepe
Kristien De Paepe
Antonio Sanchez PozoAntonio Sanchez Pozo
Antonio Sanchez Pozo
DRDimitrios Rekkas
Dimitrios Rekkas
Daisy VolmerDaisy Volmer
Daisy Volmer
CSChris Van Schravendijk
Chris Van Schravendijk
PHAR-QA, funded by the European Commission, is producing a framework of competences for pharmacy practice. The framework is in line with the EU directive on sectoral professions and takes into account the diversity of the pharmacy profession and the on-going changes in healthcare systems (with an increasingly important role for pharmacists), and in the pharmaceutical industry. PHAR-QA is asking academia, students and practicing pharmacists to rank competences required for practice. The results show that competences in the areas of “drug interactions”, “need for drug treatment” and “provision of information and service” were ranked highest whereas those in the areas of “ability to design and conduct research” and “development and production of medicines” were ranked lower. For the latter two categories, industrial pharmacists ranked them higher than did the other five groups.